Khan et al. found that the use of a preoperative GnRH agonist (gonadotropin-releasing hormone agonist, GnRHa) in patients with adenomyosis induced a decrease in MCP-1 levels and a reduction in the number of macrophages in endometrial and myometrial layers compared to those in untreated patients [7]. Here, CCL2 is linked to adenomyosis.